 Cellular Biomedicine Group, Inc. Nasdaq: CBMG Company, CBMG, we or our, a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today that it has signed a definitive merger agreement to be acquired by a newly-formed entity Parent formed on behalf of a consortium consisting of i Bizuo Tony Liu CEO of CBMG and certain other members of CBMG management Yihong Yao, Li Helen Zhang and Chengxiang Chase Dai collectively, the Management Rollover Stockholders, ii Dangdai International Group Co., Limited, Mission Right Limited, Wealth Map Holdings Limited, Earls Mill Limited, OPEA SRL, Maplebrook Limited, Full Moon Resources Limited, Viktor Pan and Zheng Zhou together with the Management Rollover Stockholders, the Consortium Rollover Stockholders and iii Yunfeng Fund III, L.P., TF Capital Fund III L.P., Velvet Investment Pte. Ltd., and Bizuo Tony Liu the Equity Investors. 